Efficacy and safety of risankizumab vs. secukinumab in patients with moderate‐to‐severe plaque psoriasis (IMMerge): results from a phase III, randomized, open‐label, efficacy–assessor‐blinded clinical trial*
British Journal of Dermatology2020Vol. 184(1), pp. 50–59
Citations Over TimeTop 10% of 2020 papers
Richard B. Warren, Andrew Blauvelt, Yves Poulin, Stefan Beeck, Matt Kelly, Tianshuang Wu, Z. Geng, C. Paul
Abstract
At week 52, risankizumab demonstrated superior efficacy and similar safety with less frequent dosing compared with secukinumab.
Related Papers
- → Secukinumab is superior to fumaric acid esters in treating patients with moderate-to-severe plaque psoriasis who are naive to systemic treatments: results from the randomized controlled PRIME trial(2017)64 cited
- → PASI (Psoriasis Area and Severity Index) in the evaluation of the clinical manifestations of psoriasis(2016)14 cited
- W jaki sposób miarodajnie oceniać nasilenie łuszczycy(2016)
- 건선 환자에서 Cyclosporine 치료 효과와 관련된 인자에 대한 후향적 연구(2021)